Idians, Paper on 'Venadafarib' Published in US Cancer Society Journal
Idions, a new drug development specialist company of Ildong Pharmaceutical Group, announced on the 7th that the non-clinical research results related to the targeted anticancer drug 'Venadafarib' have been published in the latest issue of Molecular Cancer Therapeutics.
Molecular Cancer Therapeutics is an academic journal in the field of anticancer drug translational research published by the American Association for Cancer Research (AACR).
The company explained that the Venadafarib research paper was selected by the editors as a noteworthy paper considering the innovativeness and potential of the new drug substance.
Venadafarib is an oral targeted anticancer drug candidate with a PARP (Poly ADP-ribose polymerase) inhibitory mechanism. It selectively exhibits toxicity to cancer cells, improving safety in hematological aspects compared to the existing first-generation PARP inhibitors. Idions describes it as a next-generation PARP inhibitor with potential for expanded use and indications through combination therapy with various anticancer drugs.
The journal introduced Venadafarib as a next-generation PARP inhibitor demonstrating excellent anticancer effects, with no significant side effects or harmful impacts observed in toxicity studies.
According to the research paper, Venadafarib selectively showed efficacy against cancers with BRCA mutations compared to first-generation PARP inhibitors such as Olaparib. Additionally, in in vivo tests using models of ovarian cancer, breast cancer, and pancreatic cancer, Venadafarib exhibited stronger anticancer effects at relatively lower doses than Olaparib.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- [Lee Jae-myung Administration 1 Year] Industry Ministry Highlights "Tariffs, Middle East Crisis, and Manufacturing AI as Key Achievements"
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Meanwhile, Idions was launched in 2019 as a new drug development subsidiary of Ildong Holdings, the holding company of Ildong Pharmaceutical Group, and is currently advancing clinical development of anticancer drug candidates. For Venadafarib, clinical trials of monotherapy Phase 1b/2 are underway in Korea with actual patients, along with Phase 1b clinical trials related to combination therapy for gastric cancer in Korea, the United States, and China.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
